Simple and rapid LC-MS/MS method for determination of Piribedil in human plasma

被引:0
作者
Alshishani, Anas [1 ]
Hasan, Inas [2 ]
Ghanayem, Fatima [2 ]
Al-khasawneh, Sewar [2 ]
Abu Dayah, Alaa [3 ]
机构
[1] Zarqa Univ, Fac Pharm, Zarqa, Jordan
[2] Pharmaceut Res Unit, Amman, Jordan
[3] Jordan Univ Sci & Technol, Dept Pharmaceut Technol, Irbid, Jordan
关键词
LC-MS/MS; Method Validation; Piribedil; Human plasma; Bioanalytical; Pharmacokinetic study; Bioequivalence; PARKINSONS-DISEASE; DOPAMINE AGONIST; METABOLITES; URINE;
D O I
10.3897/pharmacia.63.e86447
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A sensitive, simple, and fast LC-MS/MS method of analysis was developed and validated for the determination of piribedil in human plasma. Piribedil was extracted by protein precipitation using acetonitrile and separated on C18 Phenomenex Gemini column (150 x 4.6mm, 5 mu m) using isocratic elution of 75% of ammonium acetate buffer (10 mM) and 25% acetonitrile at a flow rate of 1 ml.min(-1) over 5 min run time. Piribedil and d8-Piribedil, as internal standard, were detected and quantified in positive ion mode via MRM at m/z 299/135 and 307/135 for piribedil and d8-piribedil, respectively. The suggested method for piribedil was validated according to FDA and EMA guidelines. The standard calibration curve was linear over the concentration range of 3.4-5952 pg.ml(-1). The intra-day precision was 2.45-9.94% and accuracy 92.78-99.97%. The inter-day precision was 2.14-5.47% and accuracy 95.73-101.99%. The recovery of analyte and IS was 96.94% and 111.18%, respectively. piribedil in plasma was stable at benchtop (short term) for 24 h, in autosampler tray for 48 h, in instrumentation room for 24 h (post-preparative), after 5 freeze-thaw cycles (-70 degrees C), and 11 days in the freezer (-70 degrees C). The validated method was successfully applied to a bioequivalence study of piribedil formulations involving 15 healthy Jordanian volunteers.
引用
收藏
页码:615 / 620
页数:6
相关论文
共 20 条
[1]   Determination of piribedil in human serum, urine and pharmaceutical dosage form by LC-DAD [J].
Altiokka, Goeksel ;
Can, Nafiz Oe. ;
Aboul-Enein, Hassan Y. .
CHROMATOGRAPHIA, 2008, 67 (11-12) :905-910
[2]  
[Anonymous], 2011, GUIDELINE BIOANALYTI
[3]   Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson's disease: physical characterization and ex vivo drug permeation through buccal mucosa [J].
Celik, Burak ;
Ozdemir, Samet ;
Demirkoz, Asli Barla ;
Uner, Melike .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (11) :1836-1845
[4]   DETERMINATION OF PIRIBEDIL IN BIOLOGICAL-MATERIALS BY GAS-LIQUID CHROMATOGRAPHY MASS FRAGMENTOGRAPHY [J].
FANELLI, R ;
FRIGERIO, A .
JOURNAL OF CHROMATOGRAPHY, 1974, 93 (02) :441-446
[5]  
Food and Drug Administration, 2018, LAP LAMBERT ACAD PUB, V5, P219, DOI [10.5958/2231-5675.2015.00035.6, DOI 10.5958/2231-5675.2015.00035.6]
[6]   Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of α2A-adrenoceptors:: A dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors [J].
Gobert, A ;
Di Cara, B ;
Cistarelli, L ;
Millan, MJ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (01) :338-346
[7]  
JENNER P, 1992, J NEUROL, V239, pS2
[8]   Determination of social and economic accessibility of drugs for treatment of Parkinson's disease on the basis of modern approaches [J].
Kotvitska, Alla ;
Prokopenko, Oleksii .
PHARMACIA, 2020, 67 (04) :215-221
[9]   Speech dysfluency exacerbated by levodopa in Parkinson's disease [J].
Louis, ED ;
Winfield, L ;
Fahn, S ;
Ford, B .
MOVEMENT DISORDERS, 2001, 16 (03) :562-565
[10]   Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease [J].
Perez-Lloret, Santiago ;
Rascol, Olivier .
CNS DRUGS, 2016, 30 (08) :703-717